Kathy Keimig, MD
Family Medicine · Gulfport, MSNPI 1760564801
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (54.3%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 35 manufacturers reported payments, led by Amgen at 49.9% of the total. Reporting peaked in 2024 at $6,786 and has fallen 73.0% since, to $1,829 in 2025. Among family medicine clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 625 payments — averaging $32.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$10K
- AbbVie$2K
- AstraZeneca$1K
- Novo Nordisk$1K
- Lilly USA, LLC$1K
- Pfizer$706
- plus $3K from 29 others
What the payments were for
- Speaking & faculty fees$8,57543%
- Travel & lodging$5243%
- Food & beverage$10,91054%
- Education$930%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 58 | $10,021 |
| AbbVie(2 entities) | 154 | $2,318 |
| AstraZeneca | 55 | $1,446 |
| Novo Nordisk | 69 | $1,170 |
| Lilly USA, LLC | 67 | $1,073 |
| Pfizer | 37 | $706 |
| Takeda Pharmaceuticals U.S.A., Inc. | 40 | $495 |
| Johnson & Johnson | 12 | $476 |
| Astellas Pharma US Inc | 20 | $305 |
| GSK | 11 | $267 |
| Abbott | 11 | $258 |
| Boehringer Ingelheim | 15 | $246 |
| Merck | 11 | $145 |
| Axsome Therapeutics, Inc. | 6 | $144 |
| Sanofi-aventis U.S. LLC | 7 | $134 |
| Biohaven Pharmaceutical Holding Company Ltd. | 7 | $129 |
| Esperion Therapeutics, Inc. | 5 | $80 |
| Exact Sciences | 4 | $75 |
| Idorsia Pharmaceuticals US Inc | 4 | $71 |
| Shire North American Group Inc | 4 | $68 |
| Medtronic | 3 | $66 |
| Mylan Specialty L.p. | 4 | $62 |
| Novartis | 2 | $47 |
| Kowa Pharmaceuticals America, Inc. | 3 | $45 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $40 |
| Sunovion Pharmaceuticals Inc. | 3 | $29 |
| Arbor Pharmaceuticals, Inc. | 2 | $27 |
| Jazz Pharmaceuticals Inc. | 1 | $27 |
| Biohaven Pharmaceuticals, Inc. | 2 | $26 |
| IBSA Pharma Inc. | 1 | $24 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| Angiodynamics, Inc. | 1 | $17 |
| Phathom Pharmaceuticals, Inc. | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $15 |
| Apria Healthcare LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$20,102 in reported general payments places this provider in the 95th percentile of 971 family medicine providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 71 | $95,271 |
| OtezlaApremilast | 11 | $52,925 |
| JardianceEmpagliflozin | 33 | $49,216 |
| MounjaroTirzepatide | 34 | $46,289 |
| VraylarCariprazine Hcl | 14 | $40,094 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $19,267 |
| Tresiba Flextouch U-200Insulin Degludec | 23 | $17,763 |
| JanuviaSitagliptin Phosphate | 11 | $15,086 |
| FarxigaDapagliflozin Propanediol | 11 | $14,072 |
| BelbucaBuprenorphine Hcl | 16 | $11,537 |
| PremarinEstrogens, Conjugated | 18 | $10,085 |
| Rosuvastatin Calcium | 346 | $3,382 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 129 | $2,666 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 13 | $2,370 |
| Gabapentin | 99 | $2,102 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,170 | $95,27171 claims |
| AmgenOtezla | $10,021 | $52,92511 claims |
| Boehringer IngelheimJardiance | $246 | $49,21633 claims |
| Lilly USA, LLCMounjaro | $1,073 | $46,28934 claims |
| AbbVieVraylar | $2,318 | $40,09414 claims |
| GSKTrelegy Ellipta | $267 | $19,26725 claims |
| MerckJanuvia | $145 | $15,08611 claims |
| AstraZenecaFarxiga | $1,446 | $14,07211 claims |
| PfizerPremarin | $706 | $10,08518 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 971 family medicine providers in Mississippi.
Other family medicine in Gulfport
- Jonathan HamiltonGulfport$16K
- Dimitrios DimitriadesGulfport$13K
- Steven SchepensGulfport$12K
- Matthew BosargeGulfport$10K
- Paul MatherneGulfport$9K
- Russell CarlisleWesson$1.6M
- Keith StokesLexington$654K
- Walter CarnahanSouthaven$146K
- Karen WhitneyWhitfield$117K
- Dava ClevelandJackson$100K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.